In our study, we evaluated the practice patterns for the use of adjuvant pertuzumab and neratinib in patients with high-risk, early-stage HER2-positive breast cancer as defined as ≥ T2 or node-positive disease. This evidence concerns the gene ERBB2 and breast carcinoma.